Millennium Management Increases Stake in Cytek Biosciences (CTKB) to 6.1%

On May 18, 2026, Millennium Management LLC and associated entities, including Millennium Group Management LLC and Israel A. Englander, filed a Schedule 13G/A with the SEC regarding their holdings in Cytek Biosciences, Inc. (CTKB). The filing indicates that as of May 11, 2026, the group has increased its beneficial ownership to 7,872,900 shares of Common Stock, representing 6.1% of the class. This reflects an increase from their previous position of 6,638,827 shares (5.2%). The shares are primarily held by Integrated Core Strategies (US) LLC, which directly owns 6,974,492 shares (5.4%). Millennium Management LLC serves as the general partner of the managing member of Integrated Core Strategies, while Israel A. Englander controls Millennium Group Management LLC, the managing member of Millennium Management LLC. The filing was made under Rule 13d-1(c), certifying that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.